

THE UNITED STATES OF AMERICA

TO ALL TO WHOM THESE PRESENTS SHALL COME:

**UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office**


May 17, 2004

**THIS IS TO CERTIFY THAT ANNEXED HERETO IS A TRUE COPY FROM
THE RECORDS OF THE UNITED STATES PATENT AND TRADEMARK
OFFICE OF THOSE PAPERS OF THE BELOW IDENTIFIED PATENT
APPLICATION THAT MET THE REQUIREMENTS TO BE GRANTED A
FILING DATE.**

APPLICATION NUMBER: 60/458,144


FILING DATE: March 27, 2003

RELATED PCT APPLICATION NUMBER: PCT/US04/09375



**By Authority of the
COMMISSIONER OF PATENTS AND TRADEMARKS**




**M. SIAS
Certifying Officer**

**PRIORITY
DOCUMENT**

**SUBMITTED OR TRANSMITTED IN
COMPLIANCE WITH RULE 17.1(a) OR (b)**

BEST AVAILABLE COPY

03/27/03
1002 U.S. PTO

3-28-03 69458144 .032705
Approved for use through 10/31/2002. OMB 0851-0032
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

PROVISIONAL APPLICATION FOR PATENT COVER SHEET

This is a request for filing a PROVISIONAL APPLICATION FOR PATENT under 37 CFR 1.53(c).

Express Mail Label No. EV022028898US

101 U.S. PTO
69458144

INVENTOR(S)				
Given Name (first and middle [if any])	Family Name or Surname	Residence (City and either State or Foreign Country)		
Michael T.	MARTIN	Durham, North Carolina		
<input type="checkbox"/> Additional inventors are being named on the _____ separately numbered sheets attached hereto				
TITLE OF THE INVENTION (500 characters max)				
PROCESS FOR PREPARING REVERSE TRANSCRIPTASE INHIBITORS				
Direct all correspondence to: CORRESPONDENCE ADDRESS				
<input checked="" type="checkbox"/> Customer Number		23347		
OR		Type Customer Number here		
<input type="checkbox"/> Firm or Individual Name		PATENT TRADEMARK OFFICE		
Address				
Address				
City	State	ZIP		
Country	Telephone	Fax		
ENCLOSED APPLICATION PARTS (check all that apply)				
<input checked="" type="checkbox"/> Specification	Number of Pages	19	<input type="checkbox"/> CD(s), Number	
<input type="checkbox"/> Drawing(s)	Number of Sheets		<input type="checkbox"/> Other (specify)	
<input type="checkbox"/> Application Data Sheet. See 37 CFR 1.76				
METHOD OF PAYMENT OF FILING FEES FOR THIS PROVISIONAL APPLICATION FOR PATENT				
<input type="checkbox"/>	Applicant claims small entity status. See 37 CFR 1.27.			FILING FEE AMOUNT (\$)
<input type="checkbox"/>	A check or money order is enclosed to cover the filing fees			
<input checked="" type="checkbox"/>	The Commissioner is hereby authorized to charge filing fees or credit any overpayment to Deposit Account Number: 07-1392			\$160.00
<input type="checkbox"/>	Payment by credit card. Form PTO-2038 is attached.			
The invention was made by an agency of the United States Government or under a contract with an agency of the United States Government.				
<input checked="" type="checkbox"/>	No.			
<input type="checkbox"/>	Yes, the name of the U.S. Government agency and the Government contract number are: _____			

Respectfully submitted,

SIGNATURE

Karen L. Prus

Date

3/27/03

TYPED or PRINTED NAME

Karen L. Prus

REGISTRATION NO.

39,337

(if appropriate)

Docket Number:

PU4975


TELEPHONE

(919) 483-2192

USE ONLY FOR FILING A PROVISIONAL APPLICATION FOR PATENT

This collection of information is required by 37 CFR 1.51. The information is used by the public to file (and by the PTO to process) a provisional application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 8 hours to complete, including gathering, preparing, and submitting the complete provisional application to the PTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Box Provisional Application, Assistant Commissioner for Patents, Washington, D.C.

Express Mail Label No.
EV022028898US

CERTIFICATE OF MAILING BY "EXPRESS MAIL" (37 CFR 1.10) Applicant(s): Michael T. MARTIN		Docket No. PU4975	
Serial No. To be assigned	Filing Date Concurrently herewith	Examiner	Group Art Unit
Invention: PROCESS FOR PREPARING REVERSE TRANSCRIPTASE INHIBITORS			
<p>I hereby certify that the following correspondence:</p> <div style="border: 1px solid black; padding: 5px; min-height: 40px;">Provisional application for patent under 37 CFR 1.53(c)</div> <p style="text-align: center;"><i>(Identify type of correspondence)</i></p> <p>is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR 1.10 in an envelope addressed to: The Assistant Commissioner for Patents, Washington, D.C. 20231 on</p> <p style="text-align: center;"><u>MARCH 27, 2003</u> (Date)</p> <div style="text-align: right; margin-top: 20px;"><div style="border-bottom: 1px solid black; display: inline-block; width: 150px;">Marjorie J. Pfeiffer</div><div style="text-align: center; font-size: small; margin-top: -5px;">(Typed or Printed Name of Person Mailing Correspondence)</div><div style="border-bottom: 1px solid black; display: inline-block; width: 150px;"></div><div style="text-align: center; font-size: small; margin-top: -5px;">(Signature of Person Mailing Correspondence)</div><div style="border: 1px solid black; display: inline-block; padding: 2px 10px; margin-top: 10px;">EV022028898US</div></div>			

Note: Each paper must have its own certificate of mailing.

PROCESS FOR PREPARING REVERSE TRANSCRIPTASE INHIBITORS

BACKGROUND OF THE INVENTION

5

The human immunodeficiency virus ("HIV") is the causative agent for acquired immunodeficiency syndrome ("AIDS"), a disease characterized by the destruction of the immune system, particularly of CD4⁺ T-cells, with attendant susceptibility to opportunistic infections, and its precursor AIDS-related complex ("ARC"), a syndrome characterized by symptoms such as persistent generalized lymphadenopathy, fever and weight loss. HIV is a retrovirus; the conversion of its RNA to DNA is accomplished through the action of the enzyme reverse transcriptase. Compounds that inhibit the function of reverse transcriptase inhibit replication of HIV in infected cells. Such compounds are useful in the prevention or treatment of HIV infection in humans.

15

Non-nucleoside reverse transcriptase inhibitors (NNRTIs), in addition to the nucleoside reverse transcriptase inhibitors gained a definitive place in the treatment of HIV-1 infections. The NNRTIs interact with a specific site of HIV-1 reverse transcriptase that is closely associated with, but distinct from, the nucleoside binding site on reverse transcriptase. NNRTIs, however, are notorious for rapidly eliciting resistance due to mutations of the amino acids surrounding the NNRTI-binding site (E. De Clercq, *Il Farmaco* 54, 26-45, 1999). Failure of long-term efficacy of NNRTIs is often associated with the emergence of drug-resistant virus strains (J. Balzarini, *Biochemical Pharmacology*, Vol 58, 1-27, 1999). Moreover, the mutations that appear in the reverse transcriptase enzyme frequently result in a decreased sensitivity to other reverse transcriptase inhibitors, which results in cross-resistance.

25

WO 00117982 discloses a series of benzophenone derivatives that when administered *in vivo* provide compounds that are useful as inhibitors of both wild type and mutant variants of HIV reverse transcriptase. Current methods for the preparation of certain intermediates useful in the synthesis of benzophenone compounds involve multi-step

30


processes that are difficult to perform on large-scale and therefore are unsuitable for manufacture. The present invention features a process for the preparation of intermediates that can be carried out in a single step, that involve no toxic reagents, and are suitable for large-scale manufacture.

5

SUMMARY OF THE INVENTION

The present invention features a process for preparing a compound of formula (I)


10



wherein

R¹ is selected from the group consisting of hydroxy, halogen, -CF₃, -NO₂ and C₁₋₈ alkyl, and C₁₋₈alkoxy comprising

15 i) reacting a compound of formula (IV)




20

with a suitable formamide in the presence of solvent and a chlorinating agent to form a compound of formula (III)


PU4975

3



(III)

- 5 ii) reacting a compound of formula (III) with a solvent and ammonia to form a compound of formula (II),



(II)

10

- iii) deprotecting the compound of formula (II) to form a compound of formula (I).


DETAILED DESCRIPTION OF THE INVENTION

15

The present invention features a process for preparing a compound of formula (I)

PU4975


4



wherein


R^1 is selected from the group consisting of hydroxy, halogen, $-CF_3$, $-NO_2$ and C_{1-8} alkyl, and C_{1-8} alkoxy comprising

5 i) reacting a compound of formula (IV)



10

with a suitable formamide in the presence of solvent and a chlorinating agent to form a compound of formula (III)




15

PU4975

5

ii) reacting a compound of formula (III) with a solvent and ammonia to form a compound of formula (II),



(II)

5

iii) deprotecting the compound of formula (II) to form a compound of formula (I).

10 As used herein, the term "alkyl", alone or in combination with any other term, refers to a straight-chain or branched-chain saturated aliphatic hydrocarbon radical containing the specified number of carbon atoms. Examples of alkyl radicals include, but are not limited to, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, pentyl, isoamyl, n-hexyl and the like.

15

The term "alkoxy" refers to an alkyl ether radical, wherein the term "alkyl" is defined above. Examples of suitable alkyl ether radicals include, but are not limited to, methoxy, ethoxy, n-propoxy, isopropoxy, n-butoxy, isobutoxy, sec-butoxy, tert-butoxy and the like, with methoxy being preferred.

20

The term "halogen" refers to fluorine, chlorine, bromine or iodine.

The present invention features a process comprising i) reacting a compound of formula (IV) with N, N-dimethylformamide in the presence of methylene chloride and oxalyl chloride to form a compound of formula (III); ii) reacting a compound of formula (III) with

25


PU4975

6

dimethoxyethane and ammonium hydroxide to form a compound of formula (II); and deprotecting a compound of formula (II) to form a compound of formula (I).

The present invention further features a process for the preparation of a compound of formula (V)


5



comprising:

10

i) reacting a compound of formula (VIII)




15

with *N, N*-dimethylformamide in the presence of solvent and a chlorinating agent to form a compound of formula (VII)


PU4975

7



ii) reacting a compound of formula (VII) with a solvent and ammonium hydroxide to form a compound of formula (VI),

5



ii) deprotecting the compound of formula (VI) to form a compound of formula (V).

10

The present invention also features a process for the preparation of a compound of formula (V) wherein the solvent of step i) is dichloromethane, the chlorinating agent is oxalyl chloride, the ammonia is ammonia hydroxide, and the solvent of step ii) is dimethoxyethane.

Step i) of processes of the present invention may be carried out by treating the compound
5 of formula (IV) with an amide such as N,N-dimethylformamide, in a suitable solvent selected
from, chloroform, toluene, dimethoxyethane, tetrahydrofuran or dioxane or preferably
methylene chloride and a halogenating agent, for example, a chlorinating agent, such as
thionyl chloride, phosphoryl chloride, phosphorous pentachloride or bromide equivalents or
preferably oxalyl chloride. The reaction may be carried out at a temperature in the range of 0°
10 to reflux, about 20°C to reflux temperature, most preferably in the range 25°C, with
methylene chloride as the solvent.

Step ii) of the processes of the present invention may be carried out in a suitable solvent
selected from an solvent such as tetrahydrofuran, dioxane or preferably dimethoxyethane.
15 The reaction may be carried out by treating a mixture of the resultant compound of step i)
with a source of ammonia such as ammonia gas, methanolic ammonia, preferably ammonium
hydroxide, or any other suitable solution of ammonia. The reaction may be carried out at
atmospheric pressure.

20 The step ii) product may be hydrolysed to the compound of formula (I) by treatment with
a solution of base such as sodium, potassium, or calcium hydroxide, or preferably lithium
hydroxide, in a water based solvent system with a suitable co-solvent such as methanol of
other alcohol or water miscible ether. The compound of formula (I) can be isolated from the
reaction solvent by adjustment of the reaction solution pH with a suitable acid source such as
25 sulphuric or preferable hydrochloric acid.

Suitable chlorinating agents may be oxalyl chloride, thionyl chloride, or phosphoryl
chloride.

30 Advantageously, an aqueous ammonia, such as ammonium hydroxide, or non aqueous
ammonia source such as NH₃ gas or methanolic ammonia may be used.

PU4975


9

Suitable solvents include dimethoxyethane, tetrahydrofuran, and dioxane.

Advantages of the processes of the present invention may include the simultaneous *in situ* protection and activation followed by immediate conversion to sulphonamide. In the processes of the present invention, the activating agent may also be the protecting agent.

The following scheme, Scheme A, represents the process according to a feature of the present invention and is not intended to limit the scope of the invention but is provided for illustration only.

Scheme A



15 wherein


R^1 is selected from the group consisting of hydroxy, halogen, $-\text{CF}_3$, $-\text{NO}_2$ and C_{1-8} alkyl, C_{1-8} alkoxy.

The present invention also features the processes as hereindescribed wherein R^1 is C_{1-8} alkyl. An embodiment is illustrated in Scheme B.

Scheme B

PU4975

10

**Example 1**

5 To a mixture of 2-aminotoluene-5-sulfonic acid (1.0wt, 1.0eq. 6.41 mol) in dichloromethane (15 vol) and N,N-dimethylformamid (0.43 wt, 1.1 equiv.) was added oxalyl chloride (1.53 wt, 2.25 equiv.) over a period of 120 minutes. Additional dichloromethane (1 volume) was added and the resulting mixture stirred at ambient temp

10 3 hours. IPC of methanol-quenched aliquot (TLC, 8% MeOH-DCM and HPLC normal phase fast LC) showed complete conversion to activated, protected intermediate. Methylene chloride was removed under gentle reflux at atmospheric pressure to approximately 5 volumes and replaced with dimethoxyethane (7.5 vol). The mixture was evaporated under vacuum with a jacket temperature of 65 degrees to approximately 5

15 volumes and diluted with additional DME (2.5 volumes). The resulting mixture was cooled to 15 degrees and treated with a solution of 28% ammonium hydroxide (2.23 vol., 3 equiv.) added over a period of 15 minutes which results in momentary dissolution of the intermediate followed quickly by precipitation of the protected intermediate. IPC (TLC, normal phase fast LC) showed complete conversion to protected sulphonamide.

20 The intermediate was filtered, and the solid washed with water (2 x 1 vol), and then placed back in the reactor. The reactor was charged with a solution of LiOH (0.45 wt., 2 equiv) in 9 : 1 water : methanol (8 vol based on original input). The resulting solution was warmed to 50 degrees for 5 hours or until IPC (TLC and normal phase fast LC) showed complete hydrolysis to a compound of formula (V). Decolorizing carbon (1.0

PU4975

11


weight %) and celite (5.0 weight %) was added and the mixture stirred briefly and filtered through filter cloth into reactor B. The solution was cooled to 25 degrees and adjusted to pH 9 with addition 6 N hydrochloric acid (approximately 1.6 vol.) over a period of 15 minutes with vigorous stirring. The solution was maintained at 45 to 55 degrees for a 2 to 4 hour period to allow conversion from the original amorphous precipitate to a crystalline solid, then cooled to 20 degrees and filtered. The resulting crystalline solid was washed with 90% water/methanol (1 volume) followed by water (2 x 1 volumes) and dried in vacuum oven at 50 degrees with nitrogen sweep for 16 hours.

PU4975

12

CLAIMS

1. A process for the preparation of a compound of formula (I)




5

wherein

R^1 is selected from the group consisting of hydroxy, halogen, $-\text{CF}_3$, $-\text{NO}_2$ and C_{1-8} alkyl, and C_{1-8} alkoxy comprising

- i) reacting a compound of formula (IV)

10




(IV)

- 15 with a suitable formamide in the presence of solvent and a chlorinating agent to form a compound of formula (III)


PU4975

13



(III)

ii) reacting a compound of formula (III) with a solvent and ammonia to form a compound of
5 formula (II),



(II)

10 iii) deprotecting the compound of formula (II) to form a compound of formula (I).


15

20

PU4975

14

2. A process according to claim 1 wherein R^1 is C_{1-8} alkyl.
3. A process for the preparation of a compound of formula (I)




5

wherein

R^1 is selected from the group consisting of hydroxy, halogen, $-CF_3$, $-NO_2$ and C_{1-8} alkyl, and C_{1-8} alkoxy comprising

- i) reacting a compound of formula (IV)


10



- 15 with *N,N*-dimethylformamide in the presence of methylene chloride and oxalyl chloride to form a compound of formula (III)


PU4975

15



(III)

ii) reacting a compound of formula (III) with dimethoxyethane and ammonia to form a compound of formula (II),



(II)

10 iii) deprotecting the compound of formula (II) to form a compound of formula (I).

4. A process according to claim 3 wherein R¹ is C₁₋₈alkyl.

5. A process according to claim 1 wherein the solvent of step i) is selected from the group
15 consisting of chloroform, toluene, dimethoxyethane, tetrahydrofuran, dioxane, and methylene chloride.


6. A process according to claim 3 wherein the solvent of step i) is selected from the group
20 consisting of chloroform, toluene, dimethoxyethane, tetrahydrofuran, dioxane, and methylene chloride.

PU4975

16

7. A process according to claim 1 wherein the chlorinating agent is selected from the group consisting of thionyl chloride, phosphoryl chloride, and oxalyl chloride.
8. A process according to claim 3 wherein the chlorinating agent is selected from the group consisting of thionyl chloride, phosphoryl chloride, and oxalyl chloride.
9. A process according to claim 1 wherein the solvent of step ii) is selected from the group consisting of tetrahydrofuran, dioxane, and dimethoxyethane.
- 10 10. A process according to claim 3 wherein the solvent of step ii) is selected from the group consisting of tetrahydrofuran, dioxane, and dimethoxyethane.
11. A process according to claim 1 wherein the ammonia is selected from ammonia gas, methanolic ammonia, and ammonium hydroxide.
12. A process according to claim 3 wherein the ammonia is selected from ammonia gas, methanolic ammonia, and ammonium hydroxide.
13. A process for the preparation of the compound of formula (V)


20



comprising:


- 25 i) reacting a compound of formula (VIII)

17




with *N, N*-dimethylformamide in the presence of solvent and a chlorinating agent to form a compound of formula (VII)

5



ii) reacting a compound of formula (VII) with a solvent and ammonium hydroxide to form a compound of formula (VI),



PU4975

18

iii) deprotecting the compound of formula (VI) to form a compound of formula (V).

14. The process according to claim 13, wherein the solvent of step i) is dichloromethane, the
5 chlorinating agent is oxalyl chloride, the ammonia is ammonia hydroxide, and the solvent of
step ii) is dimethoxyethane.

PU4975

19

ABSTRACT

The present invention is directed to processes for the synthesis of intermediates useful in the preparation of non-nucleoside reverse transcriptase inhibitors.

5

This Page is inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

☒ BLACK BORDERS

☒ IMAGE CUT OFF AT TOP, BOTTOM OR SIDES

☒ FADED TEXT OR DRAWING

☒ BLURED OR ILLEGIBLE TEXT OR DRAWING

☐ SKEWED/SLANTED IMAGES

☐ COLORED OR BLACK AND WHITE PHOTOGRAPHS

☐ GRAY SCALE DOCUMENTS

☐ LINES OR MARKS ON ORIGINAL DOCUMENT

☐ REPERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY

☐ OTHER: _____

IMAGES ARE BEST AVAILABLE COPY.

**As rescanning documents *will not* correct images
problems checked, please do not report the
problems to the IFW Image Problem Mailbox**